Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast
| Autor: | Xin Zhou, Yeli Yue, Jie Luo, Juanhui Dong, Yong Cao, Xinrui Liang, Xiaohua Zeng |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment MEDLINE Breast Neoplasms Disease 03 medical and health sciences breast cancer 0302 clinical medicine Text mining Breast cancer HER2 Internal medicine medicine Carcinoma Humans Basal cell Breast Clinical Case Report 030212 general & internal medicine PSCC skin and connective tissue diseases business.industry General Medicine Middle Aged Prognosis targeted therapy medicine.disease 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Good prognosis Neoplasm Recurrence Local business Adjuvant Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| DOI: | 10.1097/md.0000000000014654 |
| Popis: | Rationale: Primary squamous cell carcinoma (PSCC) of the breast is one of the least common types of breast cancer. Adjuvant treatment for PSCC remains an unresolved issue. Patient concerns: We reported a case of a 48-year-old postmenopausal female patients with a 2 × 2.5 cm lump presented with no symptoms. Diagnoses: This patient was diagnosed as PSCC of the breast. The original tumor and first recurrence exhibited triple negative phenotype, whereas the second recurrence was HER2-positive. Interventions: A tumorectomy with latissimus dorsi flap reconstruction for the second recurrence was performed followed by targeted therapy with trastuzumab. Outcomes: The patient had a complete remission, which was sustained over the 25 months of follow-up after the tumorectomy. Lessons: This is the first reported case in literature of a breast PSCC patient with switched immunohistochemical phenotypes during disease recurrence. Surgical resection with flap reconstruction and targeted therapy successfully treated the recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|